Vaasavaa Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 18-07-2024
- Paid Up Capital ₹ 1.42 Cr
as on 18-07-2024
- Company Age 24 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.48 Cr
as on 18-07-2024
- Satisfied Charges ₹ 12.24 Cr
as on 18-07-2024
- Revenue -51.27%
(FY 2023)
- Profit -79.93%
(FY 2023)
- Ebitda -54.28%
(FY 2023)
- Net Worth 3.59%
(FY 2023)
- Total Assets -10.86%
(FY 2023)
About Vaasavaa Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.42 Cr.
The company currently has active open charges totaling ₹16.48 Cr. The company has closed loans amounting to ₹12.24 Cr, as per Ministry of Corporate Affairs (MCA) records.
Subbarao Movva, Narasimha Polavarapu, Murali Koneru, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232PN2000PTC015122
- Company No.
015122
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Solapur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vaasavaa Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sri Dhanekula  | Director | 04-Jul-2013 | Current |
| Subbarao Movva | Director | 17-Jul-2000 | Current |
| Narasimha Polavarapu | Director | 23-Jun-2003 | Current |
| Murali Koneru | Director | 17-Jul-2000 | Current |
Financial Performance of Vaasavaa Pharmaceuticals.
Vaasavaa Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 51.27% decrease. The company also saw a substantial fall in profitability, with a 79.93% decrease in profit. The company's net worth moved up by a moderate rise of 3.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vaasavaa Pharmaceuticals?
In 2023, Vaasavaa Pharmaceuticals had a promoter holding of 63.67% and a public holding of 36.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 23 Sep 2021 | ₹15.22 Cr | Open |
Others Creation Date: 28 Feb 2021 | ₹3.00 M | Open |
Others Creation Date: 16 Jul 2020 | ₹7.13 M | Open |
How Many Employees Work at Vaasavaa Pharmaceuticals?
Vaasavaa Pharmaceuticals has a workforce of 67 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vaasavaa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vaasavaa Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
